Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2016

View Archived Issues

BioMed X and J&J to develop biofilm inhibitors for oral health applications

ChemoCentryx provides update on CCX-168

Verastem initiates phase I trial of defactinib, pembrolizumab and gemcitabine in pancreatic cancer

SolaranRx enters into CRADA with NCI to advance metastatic melanoma theranostic

Peregrine and NCCN establish research collaboration to advance development of bavituximab

C4 Therapeutics launches from Dana-Farber, enters collaboration with Roche

Principia advances two programs in clinic

ViiV Healthcare and Janssen to collaborate to develop rilpivirine and cabotegravir regimen

Gilead reports topline data from phase III studies of tenofovir alafenamide in chronic HBV

uniQure reports on low-dose cohort in phase I/II hemophilia B trial of AMT-060

X-Chem forms discovery collaboration with Sanofi

Checkpoint Therapeutics to obtain rights to Teva's oral PARP inhibitor

Aridis reports promising phase I data on Aerucin

Gruenenthal discloses CRAC blockers

NKTT-120 reduces iNKT cells in patients with sickle cell disease

Bayer Schering Pharma reports BRD4 inhibitors

The University of Montana presents SLC7A11 inhibitors

Johnson & Johnson Innovation discloses a plethora of new collaborations

XBiotech reports data from phase III European trial of Xilonix

AbbVie begins phase III program evaluating ABT-494 for rheumatoid arthritis

Gruenenthal and Akashi Therapeutics form joint drug development program for HT-100

PSMA-targeted ACCURIN shows promise for mCRPC

ImaginAb presents data on PSMA imaging agent for diagnosis of prostate cancer

PTC Therapeutics completes rolling NDA for Translarna, submits phase III data to EMA

FDA grants orphan drug designation to components of Immune Design's CMB-305

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...